Abstract LB288: Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb288
Abstract: nab-Sirolimus is an mTOR inhibitor (mTORi) approved in the US for the treatment of adult patients with locally advanced, unresectable, or metastatic malignant perivascular epithelioid cell tumor (PEComa) based on clinical efficacy and safety data… read more here.
Keywords: inactivating alterations; tsc2 inactivating; tsc1 tsc2; nab sirolimus ... See more keywords
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
Sign Up to like & getrecommendations! Published in 2023 at "AntiCancer Research"
DOI: 10.21873/anticanres.16360
Abstract: Background/Aim: Advanced sarcoma has a poor prognosis. Dysregulation of the mammalian target of rapamycin (mTOR) occurs in various types of cancer. We aimed to determine the safety and efficacy of mTOR inhibitor nab-sirolimus when combined… read more here.
Keywords: sirolimus; mutations mtor; safety efficacy; mtor pathway ... See more keywords